Webinar on

Diabetes and Cancer Management

October 08, 2021

Scientific Program

Keynote Session:

Meetings International - Conference Keynote Speaker Suzan Darwish photo

Suzan Darwish

Alexandria University, Egypt

Title: Updates of phramacoherapy of diabetes mellitus

Biography:

Dr. Suzan has completed her MSc from faculty of pharmacy, Alexandria university, egypt. Ph D in pharmacology from strathclyde university, Uk. acted as professor of pharmacology in faculty of medicine, Alexandria university, egypt from 1988 to 2003. She  acted as a Head of the Department in the same University until 2005. She is now Emeritus professor in pharmacology, Faculty of Medicine, Egypt.
Publishe 35 papers in reputed Journals and supervised 14 PhD thesis, now elected as President of Egyptian Association of advancement of Basic Medical Sciences.

Abstract:

Despite the known benefits of a healthy life style, many individuals finds it hard to maintain such a life style in the modern world, which facilitates sedentary behavior and overeating. Consequently, the prevalence of  Type-II Diabetes mellitus is predict to increase dramatically over the coming years. To counteract the resulting impact on morbidity and motality of the disease, a tremendous number of new Treatments available for diabetes was poured in to the market research lines in diabetes can be grouped in to three main categories: Technological, Biological and pharmacological with the latter category, pharmacological research appears the most effective for significantly reducing the burden of Type-II Diabetes. However the success of antibiotic medication has also been limited by their mechanism of action and side effects. A big number of promising new drugs were developed to acheive newer antidiabetic medication including oral insulin, gene therapy, the incretins, di-peptidyl peptidase-4 inhibitors, peroxisome prolifirator-activated receptor inhibitors and sodium glucose co-transporter inhibitors to treat Type-II Diabetes. However the up to date, the standard of care for diabetes management is not enough for long run benefits to diabetic patients. The aim of my talk is to provide a brief overview of current anti-diabetic drugs & updates on diabetes management for clinical usage.
Meetings International - Conference Keynote Speaker John F. Burd photo

John F. Burd

Lysulin, Inc. San Diego, CA

Title: Glucose Toxicity: The Worldwide Problem and the All-Natural Solution

Biography:

He was the founder of Dexcom, the leader in continuous glucose monitoring for people with diabetes and he has spent most of his career developing and commercializing products that empower people with diabetes to live longer, healthier lives. They came up with their patent pending formulation and launched their first product, Lysulin, in January 2018. Lysulin is a nutritional supplement, available OTC, for people with Type 2 diabetes, prediabetes and metabolic syndrome that contains three active ingredient that have all been shown to lower blood glucose levels, as well as glycated proteins, like HbA1c. They share the belief that glycated proteins are the underlying cause of diabetes complications. Lysulin also improves the lipid profile by lowering cholesterol, LDL and triglycerides and raising HDL. Lysulin holds the promise to slow or halt the progression of diabetes disease complications. Double blind, placebo controlled clinical studies are currently underway to prove that Lysulin improves glycemic control.

Abstract:

Glucose is an essential ingredient in our diet and we all need it to produce the energy for everyday living.  And while glucose is essential, too much glucose over too long of a time is toxic to our bodies.  Glucose toxicity leads to the development of Type 2 diabetes in both children and adults, demanding that our healthcare systems spend a huge amount on treating diabetes and its complications.Chronic hyperglycemia leads to insulin resistance.  Insulin is the hormone needed for glucose to enter our cells to produce energy.  Needing to make insulin in an attempt to lower blood sugar can in turn lead to an inability to make insulin.  When this happen as in the case of Type 2 diabetes, we may have to resort to injection of insulin in order to try to keep our blood glucose levels in the normal range.Glucose is not a passive bystander in our bloodstream but is a toxic and reactive compound.  Glucose reacts with all of the proteins in our body forming GLYCATED PROTEINS.  These glycated proteins progress to become what is known as ADVANCED GLYCATION ENDPRODUCTS or AGEs.  These AGEs are known to be the culprits in many disease complications including cardiovasular disease. Protein glycation is also be the cause of insulin resistance.  If insulin and the insulin receptors on cells become glycated, this changes their ability to effectively function. There is now an all-natural solution to the glucose toxicity problem.  In over 20 years of R&D and clinical studies, nutritional supplements have been proven to combat glucose toxicity.  Three important supplements having this ability are the amino acid LYSINE, the mineral ZINC and a vitamin, VITAMIN C.  Combining these three important supplements into one tablet makes a powerful weapon to combat glucose toxicity and protein glycation.  This weapon is Lysulin.
Current therapy for type 2 diabetes and the history of studies proving the effectiveness of nutritional supplements will be presented along with recent data from double blind placebo controlled studies with Lysulin.
Meetings International - Conference Keynote Speaker Jianhua Luo photo

Jianhua Luo

University of Pittsburgh, USA

Title: Gene fusion resulting from chromosome recombination causes human cancers

Biography:

Jianhua Luo has been studying molecular mechanisms of human malignancies in the last 32 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 20 years, Dr. Luo has been largely focusing on the genetic and molecular mechanism of human prostate and hepatocellular carcinomas.

Abstract:

Chromosome mutations and rearrangements are some of the hallmarks of human malignancies. Chromosomal rearrangement is frequent in human cancers. One of the consequences of chromosomal rearrangement is gene fusions in the cancer genome. We have identified a panel of fusion genes in aggressive prostate cancers. In the present study, we found that these fusion genes are present in 7 different types of human malignancies with variable frequencies. Among them, CCNH-C5orf30 and TRMT11-GRIK2 gene fusions were found in breast cancer, colon cancer, non-small cell lung cancer, esophageal adenocarcinoma, glioblastoma multiforme, ovarian cancer and liver cancer, with frequencies ranging from 12.9% to 85%. In contrast, four other gene fusions (mTOR-TP53BP1, TMEM135-CCDC67, KDM4-AC011523.2 and LRRC59-FLJ60017) are less frequent. Both TRMT11-GRIK2 and CCNH-C5orf30 are also frequently present in lymph node metastatic cancer samples from the breast, colon and ovary. Thus, detecting these fusion transcripts may have significant biological and clinical implications in cancer patient management. One of these fusion genes called MAN2A1-FER generated a constitutively activated tyrosine protein kinase.  The fusion translocates FER kinase from the cytoplasm to Golgi apparatus. The fusion protein ectopically phosphorylates the N-terminal domain of EGFR, and activates the EGFR signaling pathway in the absence of a ligand. MAN2A1-FER has been found in a variety of human malignancies. It transforms immortalized cell lines into highly aggressive cancer cells. Expression of MAN2A1-FER produces spontaneous liver cancer in animals. Cancer cells positive for MAN2A1-FER are highly sensitive to several tyrosine kinase inhibitors, and can be targeted by genome therapy intervention. Thus, targeting at MAN2A1-FER or other oncogenic fusion genes may hold promise to treat human cancer effectively.